Clinical trials
ER+ Breast Cancer clinical trials
Below are recruiting er+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 558 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06033287Recruiting
Real-world study of CDK4/6 inhibitors plus hormone therapy for advanced breast cancer
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
Changsha, HunanAges 18 years+ - NCT06817525RecruitingPhase 2
Chemo and immunotherapy before surgery for early triple-negative breast cancer
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Zhengzhou, HenanAges 18–65 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT06706570Recruiting
PIK3CA gene testing for breast cancer
This trial tests for a specific gene change (PIK3CA mutation) in your breast cancer cells. The results will help doctors decide if a targeted treatment is right for you. It's for people with hormone-receptor-positive, HER2-negative breast cancer that has spread and not yet been treated in that setting.
Milan, MIAges 18 years+ - NCT07708571Recruiting
Coaching program for women on ribociclib and aromatase inhibitor
This study tests whether a coaching program based on personality types helps women with early-stage hormone receptor-positive, HER2-negative breast cancer stick to their treatment plan. Participants must be taking ribociclib (Kisqali) and an aromatase inhibitor, and their cancer must not have spread to other organs.
Augsburg, BavariaAges 18 years+ - NCT07359404Enrolling by invitationPhase 2
Sacituzumab Govitecan plus Bevacizumab for metastatic TNBC
This trial tests a combination of two drugs, Sacituzumab Govitecan and Bevacizumab, for people with advanced triple-negative breast cancer that has already been treated. The goal is to see if the combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07278726Recruiting
Targeted removal of only suspicious lymph nodes for early breast cancer
This trial is testing a targeted surgical approach to remove only the suspicious lymph nodes under the arm for people with early-stage, hormone receptor positive, HER2 negative breast cancer. The goal is to see if this less extensive surgery is safe and effective when there is limited lymph node involvement.
Bologna, ItalyAges 18–90 - NCT05525767RecruitingPhase 4
Bevacizumab plus chemo before surgery for HER2-negative breast cancer
This trial studies whether adding bevacizumab (an anti-blood-vessel medicine) to chemotherapy before surgery improves treatment outcomes for people with HER2-negative breast cancer. It’s mainly for tumors that are stage II to IIIC and have not had prior cancer treatment.
Shijiazhuang, HebeiAges 18 years+ - NCT07622836Recruiting
Chemotherapy plus QL1706 for high-risk triple-negative breast cancer
This study tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy after surgery can help patients with aggressive triple-negative breast cancer that has spread to lymph nodes. The goal is to see if this combination prevents cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT07180693Recruiting
Breast cancer that returns after CDK4/6 inhibitor treatment
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
Bergamo, ItalyAges 18 years+ - NCT07705438Recruiting
PET scan to predict if immunotherapy works in TNBC
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
ShanghaiAges 18 years+ - NCT04265872RecruitingEarly Phase 1
Bortezomib then pembrolizumab and cisplatin for metastatic triple-negative breast cancer
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
Dallas, TexasAges 18 years+ - NCT04501523RecruitingPhase 2
ctDNA-guided immunotherapy boost after chemotherapy for triple-negative breast cancer
This Phase 2 study checks whether a blood test that looks for cancer DNA (ctDNA) can help decide who should get an extra 12-month immunotherapy treatment after standard chemotherapy and surgery. It may help reduce the chance of the cancer coming back in people with triple-negative breast cancer.
Guandong, GuangdongAges 18–80 - NCT04803539RecruitingPhase 2/Phase 3
ctDNA-guided booster treatment after chemo for triple-negative breast cancer
This trial uses a blood test called ctDNA to see who is at higher risk after surgery and standard chemotherapy for triple-negative breast cancer. If your ctDNA test is positive, you may receive an extra “boost” treatment to help reduce the chance the cancer returns.
Guandong, GuangdongAges 18–80 - NCT07243002Recruiting
Patient outcomes with ribociclib or abemaciclib for early breast cancer
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
LondonAges 18 years+ - NCT05217966Recruiting
Radiation before possible breast surgery for early ER-positive cancer
This study gives radiation to the breast before surgery to see if some people can safely delay or even skip surgery. It targets women with a small, node-negative, ER-positive breast cancer with low genetic risk.
Montreal, QuebecAges 50 years+ - NCT05228951RecruitingPhase 2
Testing four breast cancer medicines for stage II–III ER+/PR+/HER2+ cancer
This trial studies a combination of anti-cancer medicines (including trastuzumab and hormone therapy) for women with stage II–III breast cancer that is ER-, PR-, and HER2-positive. It aims to improve outcomes by attacking the cancer in different ways.
Shenyang, LiaoningAges 18–75 - NCT05341141Recruiting
Cold therapy plus compression to prevent nerve damage from chemo
This trial tests whether using cold therapy (cryotherapy) together with compression can lower the chance of numbness, tingling, or pain in the hands and feet caused by chemotherapy. It may help people planning chemotherapy for breast cancer stay more comfortable and function better.
Beijing, Beijing MunicipalityAges 20–70 - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for er+ breast cancer?
- Yes. Clin2 currently lists 558 recruiting er+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a er+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a er+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.